Two studies that examined large cohorts of stage II and III CRC [4, 79] reported that MSS cancers with a BRAF mutation had a worse prognosis compared to those with a KRAS mutation [4], and this was independent of disease stage and adjuvant treatment [79]. The gene discussed is BRAF; the disease is colorectal carcinoma.